Global Menotropin Market Size By Type (Oral Drugs, Injectable Drugs), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Menotropin Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.7 billion by 2031, growing at a CAGR of 7.2% during the forecast period from 2023 to 2031. Menotropins, also known as human menopausal gonadotropins (hMG), are widely used in fertility treatments, especially in assisted reproductive technologies (ART) like in-vitro fertilization (IVF). The rising global incidence of infertility, increasing awareness and availability of fertility treatments, and growing investments in reproductive healthcare infrastructure are key factors driving market growth.

Drivers:

1. Rising Incidence of Infertility:

Changing lifestyles, stress, environmental pollution, and delayed family planning are contributing to increased infertility rates globally. This trend has significantly elevated the demand for fertility-enhancing treatments like menotropin-based therapies.

2. Expanding Use in ART Procedures:

The number of ART cycles performed worldwide continues to increase due to improved success rates, growing societal acceptance, and supportive government initiatives. Menotropin is a primary drug used in ovarian stimulation protocols, reinforcing its demand.

3. Technological Advancements in Fertility Treatment:

The development of more refined, purified forms of menotropin and improvements in hormone delivery methods are enhancing treatment efficacy and patient compliance, thereby bolstering market adoption.

Restraints:

1. High Cost of Fertility Treatments:

Fertility treatments remain expensive, especially in developing regions, with limited insurance coverage. The cost of hormone therapies like menotropin can be a significant barrier for many patients.

2. Side Effects and Health Risks:

Use of menotropin can sometimes lead to adverse effects such as ovarian hyperstimulation syndrome (OHSS), multiple pregnancies, and other hormonal imbalances, which may deter its usage in sensitive populations.

Opportunity:

1. Growing Demand in Emerging Markets:

Rising income levels, increasing awareness, and expanding access to fertility clinics in Asia-Pacific and Latin America present vast opportunities for market expansion.

2. Strategic Collaborations and R&D:

Collaborations between biopharma companies and fertility clinics, along with investments in research to develop recombinant and bio-identical hormones, offer lucrative growth potential.

Market by System Type Insights:

Based on product type, the Highly Purified Menotropin segment dominated the market in 2023. This form offers superior safety, lower contamination risks, and better efficacy, making it the preferred choice in ART treatments. Meanwhile, Conventional Menotropin continues to maintain relevance due to its cost-effectiveness, particularly in lower-income regions.

Market by End-use Insights:

In 2023, Fertility Clinics accounted for the largest share of the menotropin market, reflecting the central role of specialized centers in delivering ART procedures. Hospitals also represent a significant end-use segment, particularly in public health-driven fertility programs in developed economies.

Market by Regional Insights:

North America held the dominant share of the global menotropin market in 2023, driven by advanced fertility care infrastructure, high treatment awareness, and strong insurance penetration. Asia-Pacific, however, is projected to witness the highest growth through 2031, fueled by a large population base, rising infertility rates, and increased investment in reproductive healthcare.

Competitive Scenario:

Key players in the global menotropin market include Ferring Pharmaceuticals, Merck KGaA, IBSA Institut Biochimique SA, EMD Serono, and Livzon Pharmaceutical Group Inc. These companies are focused on R&D for hormone therapy innovations, strategic partnerships with fertility centers, and geographical expansion.

Scope of Work – Global Menotropin Market

Key Market Developments:

March 2024 – Ferring Pharmaceuticals launched a new digital platform integrating personalized ovarian stimulation protocols with its menotropin product to enhance IVF success rates.

October 2023 – Merck KGaA expanded its fertility treatment network in Asia-Pacific through partnerships with leading fertility clinics.

June 2023 – IBSA introduced a recombinant variant of menotropin aimed at reducing the incidence of OHSS while maintaining treatment efficacy.

FAQs:

1) What is the current market size of the Global Menotropin Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Menotropin Market?

The rising incidence of infertility and increasing use of ART procedures are major growth drivers.

3) Which is the largest region during the forecast period in the Global Menotropin Market?

North America is expected to remain the leading region in terms of market share.

4) Which segment accounted for the largest market share in the Global Menotropin Market?

The Highly Purified Menotropin segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Menotropin Market?

Key players include Ferring Pharmaceuticals, Merck KGaA, IBSA Institut Biochimique SA, EMD Serono, and Livzon Pharmaceutical Group Inc.